Ginger Capsules for the Prophylactic Treatment of Migraine

Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) in Prophylactic Migraine Treatment

The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.

Patients with the diagnosis of migraine according to the IHS criteria will receive capsules of 200 mg of ginger extract (5% active ingredient) or placebo (cellulose) to be taken three times a day for 12 weeks.

Inclusion Criteria:

• Aged between 18 and 60 years old;
• Migraine diagnosis;
• Agree to sign the informed consent.

Exclusion Criteria:

• Patients with headaches not characterized as migraine;
• Pregnant or lactating women;
• Fertile and sexually active women who do not use contraception;
• Abuse of painkillers, alcohol or other drugs;
• People with hypersensitivity to ginger compounds;
• People with severe neurological diseases (e.g. epilepsy)
• People in use of anticoagulant drugs.